Ocular Therapeutix insider to sell 3,296 shares
OCULAR THERAPEUTIX, INC.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
OCULAR THERAPEUTIX, INC. (OCUL) is the issuer of common stock that Jeffrey S. Heier plans to sell under Rule 144. A notice covers a proposed sale of 3,296 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $35,532.20, tied to restricted stock vesting under a registered plan. The filing also reports that Heier sold 3,018 common shares over the prior three months for $24,745.19.
Key Figures
Key Terms
Rule 144 regulatory
Restricted Stock Vesting Under a Registered Plan financial
aggregate market value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 144 filing disclose for OCUL by Jeffrey S. Heier?
What is the nature of the OCUL securities being sold by Jeffrey S. Heier?
AI-generated analysis. How Rhea-AI works. Not financial advice.